Critics immediately decried the move as the latest example of the “revolving door” in Washington between federal regulators and the businesses they oversee.
“Such moves harm the reputation of the FDA,” said Leigh Turner, a bioethicist at the University of Minnesota, in a tweet. “Today’s news reinforces concerns that there is too cozy a relationship between the FDA and the companies it is supposed to regulate.”
Before becoming commissioner in May 2017, Gottlieb worked at the venture capital firm New Enterprise Associates, was a fellow at the American Enterprise Institute and served on the boards of several smaller companies. He also did some work for Pfizer. Since leaving the FDA in early April, he has gone back to working at New Enterprise and the AEI. He also has become a regular contributor to CNBC.
Almost every FDA commissioner in the last 40 years has joined the board of a drug or health-care company at some point after leaving the agency, Walid Gellad, an associate professor of medicine at the University of Pittsburgh, said in a tweet after Pfizer announced the news about Gottlieb.
Gellad also tweeted a table he compiled that showed that David Kessler, the FDA commissioner during the George H.W. Bush and Clinton administrations, did not join such a board. According to the table, examples of commissioners who have joined boards include Mark McClellan, who was the FDA chief during the George W. Bush administration and is on the board of Johnson & Johnson, and Robert Califf, FDA head during the Obama administration. Califf is a board member for Cytokinetics.
Stat, a Boston-based news website that covers health and medicine, reported that last year that Pfizer board members were paid more than $300,000 in cash and stock.